Nebenwirkungen · Comirnaty
Comirnaty JN.1 10 micrograms/dose concentrate for dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 46
HOS-148956 · Präparat HOS-099980
Participants 12 years of age and older – after a booster dose of Comirnaty Omicron XBB.1.5 (fourth dose or more) In a subset from Study 13 (Phase 2/3), 412 participants 12 years of age and older, who had received at least 3 doses of an authorised mRNA COVID-19 vaccine, received a booster (fourth dose or more) of Comirnaty Omicron XBB.1.5 2.0 to 24.1 months after receiving Dose 3. Participants who received a booster (fourth dose or more) of Comirnaty XBB.1.5 had a median follow-up time of 6.3 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage 75b0cac51b9a469e020fb36ff13788884d0606874aa300d07885ba25b2b8d840 · Zeichen 11185–11689 im Abschnitt